Published in Virology on November 19, 2014
Viral Therapy in Treating Patient With Liver Cancer | NCT01628640
Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. Oncotarget (2016) 0.75
Replicon RNA Viral Vectors as Vaccines. Vaccines (Basel) (2016) 0.75
Ruxolitinib and polycation combination treatment overcomes multiple mechanisms of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. J Virol (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Two CD95 (APO-1/Fas) signaling pathways. EMBO J (1998) 10.42
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol (2010) 5.07
Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science (2013) 4.14
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res (2011) 3.18
Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity (2000) 3.07
Tubulin: a factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs. Proc Natl Acad Sci U S A (1986) 2.45
Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med (2004) 2.42
The CD95 type I/type II model. Semin Immunol (2003) 2.34
Viral control of mitochondrial apoptosis. PLoS Pathog (2008) 2.21
Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus. J Virol (2001) 1.92
VSV-tumor selective replication and protein translation. Oncogene (2005) 1.88
The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res (2008) 1.75
Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol (2001) 1.75
Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis (2009) 1.72
Vesicular stomatitis virus as an oncolytic vector. Viral Immunol (2004) 1.70
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene (2000) 1.69
Visualization of intracellular transport of vesicular stomatitis virus nucleocapsids in living cells. J Virol (2006) 1.53
Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther (2005) 1.43
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol (2012) 1.34
Apoptosis: targets in pancreatic cancer. Mol Cancer (2003) 1.31
Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol (2005) 1.28
The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol (2008) 1.26
Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol Cancer (2008) 1.26
Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J Virol (2009) 1.25
Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression. J Virol (2003) 1.22
Induction of apoptotic DNA fragmentation by the infection of vesicular stomatitis virus. Virus Res (1995) 1.22
G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells. J Clin Invest (2007) 1.16
Interferons and apoptosis. J Interferon Cytokine Res (2003) 1.15
Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol (2006) 1.14
The IRF-3/Bax-mediated apoptotic pathway, activated by viral cytoplasmic RNA and DNA, inhibits virus replication. J Virol (2011) 1.13
Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling. Virology (2012) 1.12
Kinetics of virus production from single cells. Virology (2012) 1.10
VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. Mol Ther (2010) 1.08
Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol (2014) 1.07
Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection. J Neurovirol (2007) 1.06
The essential role of evasion from cell death in cancer. Adv Cancer Res (2011) 1.05
Emerging roles of FAM14 family members (G1P3/ISG 6-16 and ISG12/IFI27) in innate immunity and cancer. J Interferon Cytokine Res (2010) 1.03
Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis. J Virol (2008) 1.02
Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J Virol (2012) 1.01
Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma. Eur J Cell Biol (2010) 0.99
Essential role of caspase-8 in p53/p73-dependent apoptosis induced by etoposide in head and neck carcinoma cells. Mol Cancer (2011) 0.98
Bax-dependent mitochondrial membrane permeabilization enhances IRF3-mediated innate immune response during VSV infection. Virology (2007) 0.97
Matrix protein mutations contribute to inefficient induction of apoptosis leading to persistent infection of human neural cells by vesicular stomatitis virus. Virology (2002) 0.96
Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol (2011) 0.95
Understanding and altering cell tropism of vesicular stomatitis virus. Virus Res (2013) 0.91
Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer. Int J Cancer (2004) 0.90
Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells. J Cell Mol Med (2014) 0.87
Early activation of the mitochondrial apoptotic pathway in Vesicular Stomatitis virus-infected cells. Virus Res (2004) 0.86
Requirement of caspase-3 for efficient apoptosis induction and caspase-7 activation but not viral replication or cell rounding in cells infected with vesicular stomatitis virus. Hum Immunol (2003) 0.85
Caspase-3-like proteases are activated by infection but are not required for replication of vesicular stomatitis virus. Virus Res (2001) 0.85
Activation of endogenous type I IFN signaling contributes to persistent HCV infection. Rev Med Virol (2014) 0.85
VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1. Gene Ther (2009) 0.84
Viruses with deletions in antiapoptotic genes as potential oncolytic agents. Oncogene (2005) 0.82
Therapeutic targeting of apoptotic pathways: novel aspects in pancreatic cancer. Curr Pharm Biotechnol (2012) 0.78